The OPUS-1 study met all prespecified primary endpoints on immunogenicity and safety, supporting continued development of Vaxcyte’s 31-valent adult pneumococcal vaccine candidate.

The amended Kentucky Power agreement moves Muskie’s second 500 MW phase into 2029, while TeraWulf also said it plans to expand its revolving facility and seek additional senior secured debt.

Synopsys will receive about 1.735 million shares initially, with final settlement tied to average trading prices and due no later than January 5, 2027.

The all-cash offer values PTC at $205 a share, while Schneider plans new equity and debt financing and targets a Q3 2027 close.

The German IT services company repurchased 2.49 million shares at €3.78 apiece after shareholders tendered nearly twice the number available under the offer.

The PAID 2026-2 securitization drew 27 investors, including four new to Pagaya’s personal-loan ABS platform, as the company broadened its funding base.

OCC will clear and settle trades for IEX Options, which launched October 2 and is rolling symbols out in six planned tranches through the end of the month.

CSL will also fund Phase 2 and planned Phase 3 development of lixudebart, while Alentis can earn up to $1.2 billion in commercial milestones and 45% of global profits.

Athabasca holders can elect cash or Cenovus shares, subject to pro-ration, with a shareholder vote expected in late November and closing targeted for December.

AstraZeneca’s $2 billion purchase of Summit convertible preferred stock has closed, giving it rights equivalent to about 12% of outstanding common shares as the companies expand ivonescimab clinical work.